Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 357.39K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Robb Gary Charles intends to sell 11,000 shares of its common stock on Jul 1, with a total market value of approximately $357.39K

Futu News02:00

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 162.45K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on Jul 1, with a total market value of approximately $162.45

Futu News01:49

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 324.9K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Guyer William intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $324.9K. G

Futu News01:34

Corcept Therapeutics Price Target Maintained With a $35.00/Share by Piper Sandler

Corcept Therapeutics Price Target Maintained With a $35.00/Share by Piper Sandler

Dow JonesJul 1 21:54

Piper Sandler Reiterates Overweight on Corcept Therapeutics, Maintains $35 Price Target

Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics with a Overweight and maintains $35 price target.

Analyst UpgradesJul 1 21:44

Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $35

Piper Sandler analyst David Amsellem maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41

Futu NewsJul 1 19:31 · Ratings